Fred Middleton Acquires 248,972 Shares of CalciMedica (NASDAQ:CALC) Stock

CalciMedica Inc. (NASDAQ:CALC) Director Fred Middleton bought 248,972 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the purchase, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This represents a 30.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

CalciMedica Stock Up 4.4%

Shares of CALC stock opened at $1.03 on Wednesday. The stock has a market cap of $16.27 million, a P/E ratio of -0.79 and a beta of 0.97. CalciMedica Inc. has a 52 week low of $0.46 and a 52 week high of $7.20. The company’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $1.87.

Analyst Upgrades and Downgrades

Separately, Oppenheimer decreased their target price on CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CALC. Envestnet Asset Management Inc. grew its position in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after acquiring an additional 34,386 shares in the last quarter. Cetera Investment Advisers raised its position in CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the period. PVG Asset Management Corp bought a new stake in shares of CalciMedica in the 4th quarter valued at approximately $302,000. Renaissance Technologies LLC lifted its stake in shares of CalciMedica by 26.1% in the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of CalciMedica in the 4th quarter valued at approximately $127,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.